Table 1.
Median and interdecile ranges for concentrations (nmol/L) of measured androgens and androgen metabolites among endometrial cancer case subjects and control subjects
| Androgen or androgen metabolite | Median (10th–90th percentile) |
P * | |
|---|---|---|---|
| Cases (n = 313) | Controls (n = 354) | ||
| Parent androgens | |||
| DHEA | 5.5 (2.2–11.1) | 5.0 (2.1–10.7) | .10 |
| DHEAS | 1193.3 (512.9–3017.5) | 1161.8 (423.6–2657.9) | .10 |
| Androstenedione | 1.4 (0.9–2.4) | 1.3 (0.7–2.3) | .02 |
| Testosterone | 0.7 (0.3–1.3) | 0.6 (0.3–1.0) | .001 |
| 5α pathway | |||
| 5α-Androstanedione | 1.2 (0.8–2.4) | 1.3 (0.7–2.3) | .64 |
| DHT | 0.2 (0.1–0.3) | 0.2 (0.1–0.3) | .34 |
| DHTS | 1.1 (0.5–2.4) | 1.1 (0.4–2.3) | .29 |
| ADT | 0.5 (0.4–0.9) | 0.5 (0.4–0.9) | .27 |
| ADT-G | 23.3 (9.1–65.7) | 19.7 (7.0–53.0) | .01 |
| 3α-diol-3G | 1.6 (0.7–4.3) | 1.4 (0.5–3.7) | .01 |
| 3α-diol-17G | 1.3 (0.5–3.4) | 1.2 (0.5–3.0) | .10 |
| Marker of androgenic activity | |||
| Sum of ADT-G + 3α-diol-3G + 3α-diol-17G | 26.4 (10.6–72.1) | 23.1 (8.4–58.3) | .01 |
| 5β pathway | |||
| Etio-G | 37.7 (14.7–87.6) | 33.6 (12.6–89.7) | .05 |
| Parent estrogens† | |||
| Unconjugated estrone | 73.7 (37.3–155.8) | 55.4 (30.1–115.9) | <.0001 |
| Unconjugated estradiol | 20.0 (6.3–55.0) | 11.6 (4.0–38.8) | <.0001 |
| Ratios | |||
| 5α-androstanedione: Androstenedione | 0.9 (0.4–2.0) | 1.0 (0.4–2.4) | .15 |
| Unconjugated estrone: Androstenedione | 49.8 (28.8–103.6) | 41.2 (23.4–97.8) | <.0001 |
| DHT: Testosterone | 0.3 (0.1–0.6) | 0.3 (0.2–0.6) | .01 |
| Unconjugated estradiol: Testosterone | 30.4 (10.6–74.8) | 18.4 (7.2–67.2) | <.0001 |
*
P value from Wilcoxon rank sum tests comparing distributions of a given hormone or hormone metabolite between case subjects and control subjects.
†
Estrogens were previously measured (concentrations in pmol/L); see Brinton et al. (2). 3α-diol-3G = 5α-androstane 3α,17β diol-3-glucuronide; 3α-diol-17G = 5α-androstane 3α,17β diol-17-glucuronide; ADT = androsterone; ADT-G = ADT-glucuronide; CI = confidence interval; DHEA = dehydroepiandrosterone; DHEAS = dehydroepiandrosterone sulfate; DHT = dihydrotestosterone; DHTS = dihydrotestosterone sulfate; etio-G = etiocholanolone-glucuronide.